u/Heavy_Snow2152

https://www.biopharmadive.com/news/makary-fda-commissioner-resign-trump/819757/

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target.

The company is developing therapies for devastating neurological conditions, the analyst tells investors in a research note. The firm says NervGen’s lead candidate, NVG-291, is entering Phase 3 development for chronic tetraplegia in patients with incomplete cervical spinal cord injury. It believes the drug offers a “differentiated” mechanism based on key scientific principles.